Valuation Novo Nordisk A/S

Stocks

Market Closed - Nasdaq Copenhagen Other stock markets 18:20:00 10/07/2026 +03			5-day change	1st Jan Change
322.25 ^DKK	+0.66%		-1.42%	-0.92%

07-11	Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig In Phase 3 Hemophilia a Frontier Extension Study	CI
07-10	Nordic stocks in North America: Astra Zeneca rose 0.6%	FW

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,674,992	2,118,803	3,112,331	2,772,285	1,445,242	1,426,216	-	-
Change	-	26.5%	46.89%	-10.93%	-47.87%	-1.32%	-	-
Enterprise Value (EV) ¹	1,684,152	2,121,013	3,109,107	2,848,764	1,549,238	1,553,330	1,552,349	1,537,688
Change	-	25.94%	46.59%	-8.37%	-45.62%	0.26%	-0.06%	-0.94%
P/E	35.4x	38.4x	37.5x	27.6x	14.1x	14.2x	15.2x	14x
PBR	24x	25.6x	29.4x	19.3x	-	6.24x	5.56x	4.94x
PEG	-	2.2x	0.7x	1.3x	7.98x	-11.43x	-2.17x	1.55x
Capitalization / Revenue	11.9x	12x	13.4x	9.55x	4.68x	4.86x	4.77x	4.47x
EV / Revenue	12x	12x	13.4x	9.81x	5.01x	5.3x	5.19x	4.82x
EV / EBITDA	26x	25.8x	27.8x	19.3x	10.4x	10.9x	10.9x	10.1x
EV / EBIT	28.7x	28.4x	30.3x	22.2x	12.1x	12.8x	12.9x	11.9x
EV / FCF	57.4x	37x	45.5x	38.6x	26.3x	33.6x	21.8x	19.1x
FCF Yield	1.74%	2.7%	2.2%	2.59%	3.81%	2.98%	4.58%	5.23%
Dividend per Share ²	5.2	6.2	9.4	11.4	11.7	11.35	11.03	12.12
Rate of return	1.41%	1.32%	1.35%	1.83%	3.6%	3.52%	3.42%	3.76%
EPS ²	10.37	12.22	18.62	22.63	23.03	22.74	21.15	23.06
Distribution rate	50.1%	50.7%	50.5%	50.4%	50.8%	49.9%	52.2%	52.5%
Net sales ¹	140,800	176,954	232,261	290,403	309,064	293,298	299,205	318,724
EBITDA ¹	64,669	82,171	111,987	147,446	149,640	142,561	142,295	152,345
EBIT ¹	58,644	74,809	102,574	128,339	127,658	121,819	120,228	129,391
Net income ¹	47,757	55,525	83,683	100,988	102,434	99,105	94,050	101,012
Net Debt ¹	9,160	2,210	-3,224	76,479	103,996	127,114	126,133	111,472
Reference price ²	367.50	469.00	698.10	624.20	325.25	322.25	322.25	322.25
Nbr of stocks (in thousands)	4,557,801	4,517,704	4,458,288	4,441,340	4,443,479	4,425,806	-	-
Announcement Date	2/2/22 A	2/1/23 A	1/31/24 A	2/5/25 A	2/3/26 A	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
NOVO NORDISK A/S	14.17x	5.3x	10.9x	3.52%	218B
ELI LILLY AND COMPANY	34.92x	12.63x	25.81x	0.57%	1,060B
JOHNSON & JOHNSON	27.42x	6.3x	17.1x	2.08%	619B
ABBVIE INC.	30.1x	7.34x	15.02x	2.76%	438B
ROCHE HOLDING AG	17.98x	4.45x	11.01x	2.97%	333B
NOVARTIS AG	21.52x	5.52x	13.36x	2.86%	282B
ASTRAZENECA PLC	21.56x	4.53x	12.65x	1.94%	267B
AMGEN INC.	23.78x	6.31x	11.12x	2.78%	196B
GILEAD SCIENCES, INC.	-46.02x	5.6x	31.12x	2.5%	161B
PFIZER INC.	12.29x	3.03x	7.56x	7.14%	138B
Average	15.77x	6.10x	15.57x	2.91%	371.17B
Weighted average by Cap.	23.44x	7.67x	17.77x	2.19%